Longitude (Cayman)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.4M Buy
280,000
+151,100
+117% +$6.49M 4.27% 6
2026
Q1
$4.74M Sell
128,900
-252,900
-66% -$12M 1.94% 22
2025
Q4
$19.4M Buy
+381,800
New +$19.5M 8.39% 2
2024
Q4
$3.87M Buy
+45,000
New +$4.87M 0.81% 24

Other funds holding NVO

Longitude (Cayman)'s NVO Position: Q2 2026 in Review

Longitude (Cayman) increased its Novo Nordisk (NVO) stake by 7.1% in Q2 2026, buying an estimated $129K and bringing the position to 45,000 shares worth $2.16M. The position accounts for 0.69% of the portfolio, ranked #35.

Longitude (Cayman) first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Longitude (Cayman) held 45,000 shares of Novo Nordisk worth $2.16M as of Q2 2026.
  • Longitude (Cayman) bought 3,000 Novo Nordisk shares in Q2 2026, an estimated $129K.
  • Novo Nordisk made up 0.69% of Longitude (Cayman)'s portfolio in Q2 2026, its #35 holding.
  • Longitude (Cayman) first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Longitude (Cayman)'s 13F filing for Q2 2026, filed 12 Aug 2026.